Pharmacy Research on Prexasertib
By Carmel Sampson, PharmD candidate
As a part of my studies at AUHS School of Pharmacy, I selected Research as an elective and performed a retrospective review of 8 clinical trials using the drug candidate Prexasertib as an intervention in cancer patients. Prexasertib is a Checkpoint 1 Kinase inhibitor and falls under the drug class of Immune Checkpoint Inhibitors (ICIs). In my research, I wanted to determine the type and severity of the side effects associated with Prexasertib as an evaluation of the drug’s safety in comparison to currently used ICIs. I hypothesized that the side effects of the new ICI drug candidate Prexasertib would be similar to the side effects of currently used ICI drugs in cancer patients, but that additional side effects would manifest. My results showed that Prexasertib treatment exhibited a unique profile of common side effects with a higher incidence of hematologic effects than typically associated with ICIs. However, several studies also indicated that these side effects were reversible or manageable, especially through dose adjustments. Furthermore, no additional side effects were identified, and there was a lower incidence of the other side effects more common to ICIs, such as diarrhea, rash, and dry cough. Although further research is necessary to determine the safety and efficacy of Prexasertib, these results indicate its promise as a new ICI drug. Lastly, I compiled my research into a poster presentation titled “Prexasertib in Cancer Therapy: An Analysis of Common Adverse Effects and Potential as a New Immune Checkpoint Inhibitor.”
I was then given the opportunity to present my poster at the CSHP Seminar 2024 through the sponsorship of the Long Beach CSHP pharmacist chapter. Presenting my poster was a very satisfying experience that allowed me to see all of my hard work pay off. I also gained a new experience in presenting my own research at this level for the first time. I really enjoyed the opportunity to showcase my findings and add to the literature as well as develop my skills as a presenter. I also found it beneficial to see other presentations and exhibits. When I was surrounded by so many other presenters, I felt like I was part of a community. Speaking with the other exhibitors gave me the chance to ask questions and learn about different topics and opportunities. The presentations covered a wide range of areas including new medications, compounding facilities, robotics and technology, and internship opportunities. I also had amazing and inspiring conversations about life and the future, including different Pharmacy career avenues to pursue. Overall, the CSHP Seminar 2024 was an experience that I will never forget, and I am grateful I had the opportunity to enjoy it.